Ridgeback Capital Investments L.P. Takes $560,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Ridgeback Capital Investments L.P. acquired a new stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 359,231 shares of the company’s stock, valued at approximately $560,000. Pyxis Oncology makes up 100.0% of Ridgeback Capital Investments L.P.’s portfolio, making the stock its biggest position. Ridgeback Capital Investments L.P. owned approximately 0.60% of Pyxis Oncology at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC raised its stake in shares of Pyxis Oncology by 275.0% during the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after acquiring an additional 46,997 shares during the last quarter. American Century Companies Inc. increased its holdings in Pyxis Oncology by 88.1% in the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock valued at $468,000 after purchasing an additional 140,498 shares during the period. Renaissance Technologies LLC raised its position in Pyxis Oncology by 83.0% during the 4th quarter. Renaissance Technologies LLC now owns 293,354 shares of the company’s stock worth $458,000 after purchasing an additional 133,018 shares during the last quarter. Sei Investments Co. acquired a new position in Pyxis Oncology during the 4th quarter worth about $95,000. Finally, Caption Management LLC bought a new stake in shares of Pyxis Oncology in the 4th quarter valued at about $35,000. Institutional investors own 39.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Pyxis Oncology has an average rating of “Moderate Buy” and an average target price of $9.00.

Pyxis Oncology Trading Down 10.1%

Shares of PYXS opened at $1.07 on Thursday. The firm’s fifty day simple moving average is $1.05 and its two-hundred day simple moving average is $1.68. Pyxis Oncology, Inc. has a 12 month low of $0.83 and a 12 month high of $5.39. The stock has a market capitalization of $66.28 million, a P/E ratio of -1.04 and a beta of 1.15.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.01. The business had revenue of $16.15 million for the quarter. As a group, research analysts predict that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.